The ART of tumor immune escape

The ART of tumor immune escape

We recently identified the adenosine-5′-diphosphate (ADP)-ribosyltransferase-1 (ART1) as a novel immune checkpoint expressed by cancer cells. ART1 utilizes free nicotinamide adenine dinucleotide (NAD + ) in the tumor microenvironment (TME) to mono-ADP-ribosylate (MARylate) the P2X7 receptor (P2X7R)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncoimmunology 2022-12, Vol.11 (1), p.2076310-2076310
Hauptverfasser: Wennerberg, Erik, Mukherjee, Sumit, Sainz, Ricardo M., Stiles, Brendon M.
Format: Artikel
Sprache:eng
Schlagworte:
Adenosine Diphosphate
ADP Ribose Transferases - metabolism
Author’s View
CD38
CD8 T cells
Cell Death
immune escape
lung cancer
mono-ADP-ribosylation
NAD - metabolism
NAD - pharmacology
NAD-induced cell death
P2X7 receptor
Tumor Escape
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We recently identified the adenosine-5′-diphosphate (ADP)-ribosyltransferase-1 (ART1) as a novel immune checkpoint expressed by cancer cells. ART1 utilizes free nicotinamide adenine dinucleotide (NAD + ) in the tumor microenvironment (TME) to mono-ADP-ribosylate (MARylate) the P2X7 receptor (P2X7R) on CD8 T cells, resulting in NAD-induced cell death (NICD) and tumor immune resistance. This process is blocked by therapeutic antibody targeting of ART1.
ISSN:2162-402X
2162-4011
2162-402X
DOI:10.1080/2162402X.2022.2076310